246 related articles for article (PubMed ID: 22243995)
1. Why do results conflict regarding the prognostic value of the methylation status in colon cancers? The role of the preservation method.
Tournier B; Chapusot C; Courcet E; Martin L; Lepage C; Faivre J; Piard F
BMC Cancer; 2012 Jan; 12():12. PubMed ID: 22243995
[TBL] [Abstract][Full Text] [Related]
2. Rare CpG island methylator phenotype in ulcerative colitis-associated neoplasias.
Konishi K; Shen L; Wang S; Meltzer SJ; Harpaz N; Issa JP
Gastroenterology; 2007 Apr; 132(4):1254-60. PubMed ID: 17408633
[TBL] [Abstract][Full Text] [Related]
3. Aberrant methylation of different DNA repair genes demonstrates distinct prognostic value for esophageal cancer.
Ling ZQ; Li P; Ge MH; Hu FJ; Fang XH; Dong ZM; Mao WM
Dig Dis Sci; 2011 Oct; 56(10):2992-3004. PubMed ID: 21674174
[TBL] [Abstract][Full Text] [Related]
4. Improved results of LINE-1 methylation analysis in formalin-fixed, paraffin-embedded tissues with the application of a heating step during the DNA extraction process.
Wen X; Jeong S; Kim Y; Bae JM; Cho NY; Kim JH; Kang GH
Clin Epigenetics; 2017; 9():1. PubMed ID: 28149329
[TBL] [Abstract][Full Text] [Related]
5. Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients.
Mur P; Rodríguez de Lope Á; Díaz-Crespo FJ; Hernández-Iglesias T; Ribalta T; Fiaño C; García JF; Rey JA; Mollejo M; Meléndez B
J Neurooncol; 2015 May; 122(3):441-50. PubMed ID: 25682093
[TBL] [Abstract][Full Text] [Related]
6. Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells.
Koutsimpelas D; Pongsapich W; Heinrich U; Mann S; Mann WJ; Brieger J
Oncol Rep; 2012 Apr; 27(4):1135-41. PubMed ID: 22246327
[TBL] [Abstract][Full Text] [Related]
7. MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events.
de Vogel S; Weijenberg MP; Herman JG; Wouters KA; de Goeij AF; van den Brandt PA; de Bruïne AP; van Engeland M
Ann Oncol; 2009 Jul; 20(7):1216-22. PubMed ID: 19164452
[TBL] [Abstract][Full Text] [Related]
8. Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis.
Mikeska T; Bock C; El-Maarri O; Hübner A; Ehrentraut D; Schramm J; Felsberg J; Kahl P; Büttner R; Pietsch T; Waha A
J Mol Diagn; 2007 Jul; 9(3):368-81. PubMed ID: 17591937
[TBL] [Abstract][Full Text] [Related]
9. Promoter methylation status of hMLH1, hMSH2, and MGMT genes in colorectal cancer associated with adenoma-carcinoma sequence.
Lee KH; Lee JS; Nam JH; Choi C; Lee MC; Park CS; Juhng SW; Lee JH
Langenbecks Arch Surg; 2011 Oct; 396(7):1017-26. PubMed ID: 21706233
[TBL] [Abstract][Full Text] [Related]
10. CpG island methylation of the MLH1, MGMT, DAPK, and CASP8 genes in cancerous and adjacent noncancerous stomach tissues.
Kupčinskaitė-Noreikienė R; Skiecevičienė J; Jonaitis L; Ugenskienė R; Kupčinskas J; Markelis R; Baltrėnas V; Sakavičius L; Semakina I; Grižas S; Juozaitytė E
Medicina (Kaunas); 2013; 49(8):361-6. PubMed ID: 24509146
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma.
An C; Choi IS; Yao JC; Worah S; Xie K; Mansfield PF; Ajani JA; Rashid A; Hamilton SR; Wu TT
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):656-63. PubMed ID: 15701853
[TBL] [Abstract][Full Text] [Related]
12. Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.
Li Z; Zhang H; Yang J; Hao T; Li S
Cell Biol Int; 2012 May; 36(5):427-32. PubMed ID: 21864295
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma.
Suehiro Y; Wong CW; Chirieac LR; Kondo Y; Shen L; Webb CR; Chan YW; Chan AS; Chan TL; Wu TT; Rashid A; Hamanaka Y; Hinoda Y; Shannon RL; Wang X; Morris J; Issa JP; Yuen ST; Leung SY; Hamilton SR
Clin Cancer Res; 2008 May; 14(9):2560-9. PubMed ID: 18451217
[TBL] [Abstract][Full Text] [Related]
14. CpG island methylator phenotype-positive tumors in the absence of MLH1 methylation constitute a distinct subset of duodenal adenocarcinomas and are associated with poor prognosis.
Fu T; Pappou EP; Guzzetta AA; Jeschke J; Kwak R; Dave P; Hooker CM; Morgan R; Baylin SB; Iacobuzio-Donahue CA; Wolfgang CL; Ahuja N
Clin Cancer Res; 2012 Sep; 18(17):4743-52. PubMed ID: 22825585
[TBL] [Abstract][Full Text] [Related]
15. B vitamins, methionine and alcohol intake and risk of colon cancer in relation to BRAF mutation and CpG island methylator phenotype (CIMP).
Schernhammer ES; Giovannucci E; Baba Y; Fuchs CS; Ogino S
PLoS One; 2011; 6(6):e21102. PubMed ID: 21738611
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic Risk Factor Distributions for MLH1 Promoter Region Methylation in CIMP-Positive Tumors.
Levine AJ; Phipps AI; Baron JA; Buchanan DD; Ahnen DJ; Cohen SA; Lindor NM; Newcomb PA; Rosty C; Haile RW; Laird PW; Weisenberger DJ
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):68-75. PubMed ID: 26512054
[TBL] [Abstract][Full Text] [Related]
17. Pyrosequencing assays to study promoter CpG site methylation of the O6-MGMT, hMLH1, p14ARF, p16INK4a, RASSF1A, and APC1A genes.
Löf-Ohlin ZM; Nilsson TK
Oncol Rep; 2009 Mar; 21(3):721-9. PubMed ID: 19212632
[TBL] [Abstract][Full Text] [Related]
18. Quantitative evaluation of CpG island methylation in hyperplastic polyps.
Vaughn CP; Wilson AR; Samowitz WS
Mod Pathol; 2010 Jan; 23(1):151-6. PubMed ID: 19855373
[TBL] [Abstract][Full Text] [Related]
19. Promoter methylation status of hMLH1, MGMT, and CDKN2A/p16 in colorectal adenomas.
Psofaki V; Kalogera C; Tzambouras N; Stephanou D; Tsianos E; Seferiadis K; Kolios G
World J Gastroenterol; 2010 Jul; 16(28):3553-60. PubMed ID: 20653064
[TBL] [Abstract][Full Text] [Related]
20. Correlation of MLH1 and MGMT expression and promoter methylation with genomic instability in patients with thyroid carcinoma.
Santos JC; Bastos AU; Cerutti JM; Ribeiro ML
BMC Cancer; 2013 Feb; 13():79. PubMed ID: 23414134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
